Grover S S, Sharma Meenakshi, Pasha S T, Singh Gajendera, Lal Shiv
National Institute of Commnnnunicable Diseases, 22-Shamnath Marg, Delhi-10054.
J Commun Dis. 2004 Mar;36(1):17-26.
Extended spectrum beta-lactamases (ESBLs) are plasmid mediated enzymes capable of hydrolyzing penicillins, broad spectrum-cephalosporins and monobactams. The ESBL producing K. pneumoniae strains are being reported from around the world including India. The present study was taken up to evaluate the ESBL production and in-vitro susceptibility of K. pneumoniae isolates from a hospital. The bacterial isolates collected during 2003 included 51 K. pneumoniae biochemically confirmed isolates from 395 patients admitted in various wards of a major hospital in New Delhi. The isolates were from pus, wound, pleural fluid, urine and tracheal aspirate of patients attending respiratory, urology and burns wards. Antimicrobial susceptibility was carried out by Kirby Bauer's disc diffusion technique using NCCLS criteria. A screening of ESBL production was done by Double-disc synergy test (DDST) and using E-test ESBL strips. The frequency of resistance among K. pneumoniae for the cephalosporins (cefoxitin, cefuroxime, cefotaxime, ceftazidime, and cefepime) and non-cephalosporins (aztreonam, piperacillin, chloramphenicol and trimethoprim-sulfamethoxazole) were in the range of 39.2-88.0% and 51.0-90.2% respectively. 14 different antimicrobial resistance profiles were recognized ranging from resistance to only four (n=6, 11.7%) to as many as ten (n=9, 17.7%). Among the 51 isolates of K. pneumoniae strains, a total of 36 (70.6%) could be identified as ESBL producers, that correlates with the high frequency of multi-drug resistant K. pneumoniae The study shows alarming rise in ESBL production among K. pneumoniae strains and high rate of resistance to a wide range of cephalosporin and non-cephalosporin group of antimicrobials.
超广谱β-内酰胺酶(ESBLs)是由质粒介导的酶,能够水解青霉素、广谱头孢菌素和单环β-内酰胺类抗生素。包括印度在内的世界各地均有产ESBLs的肺炎克雷伯菌菌株的报道。本研究旨在评估某医院肺炎克雷伯菌分离株的ESBLs产生情况及体外药敏性。2003年收集的细菌分离株包括从新德里一家大型医院各病房收治的395例患者中经生化确认的51株肺炎克雷伯菌。这些分离株来自呼吸科、泌尿科和烧伤科患者的脓液、伤口、胸腔积液、尿液及气管吸出物。采用Kirby Bauer纸片扩散法,依据美国国家临床实验室标准化委员会(NCCLS)标准进行药敏试验。通过双纸片协同试验(DDST)及使用E-test ESBL试纸条对ESBLs产生情况进行筛查。肺炎克雷伯菌对头孢菌素类(头孢西丁、头孢呋辛、头孢噻肟、头孢他啶和头孢吡肟)和非头孢菌素类(氨曲南、哌拉西林、氯霉素和复方磺胺甲恶唑)的耐药率分别在39.2% - 88.0%和51.0% - 90.2%之间。共识别出14种不同的耐药谱,从仅对4种抗生素耐药(n = 6,11.7%)到对多达10种抗生素耐药(n = 9,17.7%)。在51株肺炎克雷伯菌菌株中,共有36株(70.6%)可鉴定为产ESBLs菌株,这与多重耐药肺炎克雷伯菌的高发生率相关。该研究显示肺炎克雷伯菌菌株中ESBLs产生情况呈惊人上升趋势,且对多种头孢菌素类和非头孢菌素类抗菌药物的耐药率很高。